

## Share Purchase Plan Timetable Extension

[CardieX Limited](#) (ASX: CDX) (CardieX, the Company) provides an update to the Share Purchase Plan (SPP) timetable which was announced on 26 August 2022 (refer to announcement 'CDX Announces SPP Launch, Booklet & Timetable'). The Company has decided to extend the SPP offer closure date by one (1) business day, to 26 September 2022, as a result of the National Day of Mourning and ASX closure on the 22 September 2022 public holiday.

The SPP offer was made at A\$0.30 per share, which represents a 12.25% discount to the Company's ten (10) day volume weighted average price of Shares traded on the ASX prior to the announcement of the SPP on Friday, 26 August 2022. The SPP booklet which has full details of the SPP was sent to all shareholders either by email or by post. Shareholders can also access the SPP booklet online at: <https://www2.asx.com.au/markets/trade-our-cash-market/announcements.cdx>

The revised (revisions are in bold text) indicative timetable for the completion of the SPP is as follows:

Event	Indicative Date
Record Date	Thursday, 25 August 2022
Announcement of SPP and SPP Opens	Friday, 26 August 2022
Documentation Sent	Wednesday, 31 August 2022
SPP Closes	<b>Monday, 26 September 2022</b>
Announcement of Demand and Scale Back	<b>Wednesday, 28 September 2022</b>
Allotment and Issue of SPP Shares	<b>Thursday, 29 September 2022</b>
ASX Quotation of SPP Shares	<b>Friday, 30 September 2022</b>
Dispatch of Shareholder Statements for SPP Participants	<b>Monday, 4 October 2022</b>
<i>This timetable is indicative only and subject to change at the discretion of CardieX and subject to the Listing Rules. All dates are references to Sydney (AEST) time. CardieX reserves the right to extend the closing date, accept late applications or withdraw the SPP without prior notice.</i>	

If Shareholders have any queries on how to participate including on how to access the application please use the contact details on your SPP booklet or consult your financial or other professional adviser.

**Approved by the Board of Directors and Released by Jarrod White, Director.**

For more information, please contact:

**Investor Relations**

Rod Hinchcliffe

[rod.hinchcliffe@mcpartners.com.au](mailto:rod.hinchcliffe@mcpartners.com.au)

**Media Relations**

Melissa Hamilton

[melissa.hamilton@mcpartners.com.au](mailto:melissa.hamilton@mcpartners.com.au)

**Investor Relations – USA**

Matt Selinger

Managing Director, Integrous Communications

[mselinger@integcom.com](mailto:mselinger@integcom.com)

**About CardieX**

CardieX is a global health technology company. Its [ATCOR](#) subsidiary is a world leader in medical devices for hypertension, cardiovascular disease, and other vascular health disorders based on the Company's "gold standard" SphygmoCor® central blood pressure technology. CardieX's [CONNEQT](#) subsidiary develops and markets medical devices, digital solutions, and wearables for home health, primary clinician, and other healthcare channels. CardieX is listed on the Australian Stock Exchange (ASX:CDX).